Skip to content
    BBNX
    Earnings call· Jun 2026(Q2 FY26)

    Beta Bionics Q2 FY26 earnings call BBNX

    Jul 29, 2026 Source

    Executive summary

    Beta Bionics Q2 FY26 — Strong Revenue Growth and Pipeline Progress

    Beta Bionics demonstrated strong commercial momentum in Q2 FY26, driven by robust Islet sales and a successful pharmacy channel strategy. The company is making significant progress across its innovation pipeline, including the MINT patch pump, bi-hormonal system, and indication expansion for Islet, positioning it for future growth. Despite increased operating expenses to support commercial and R&D initiatives, management reiterated full-year revenue guidance and raised its gross margin outlook, reflecting confidence in its underlying profitability and market strategy.

    Highlights

    5

    • Net sales reached $32 million, growing approximately 38% year-over-year.

    • Gross margin expanded by 524 basis points year-over-year to 59%.

    • New patient starts increased more than 10% but less than 20% compared to the prior quarter.

    • 69% of new patient starts came from people utilizing multiple daily injections, expanding the insulin pump market.

    • The company holds approximately $225 million in cash, cash equivalents, and short/long-term investments as of June 30, 2026.

    Concerns

    3

    • Total operating expenses increased 37% year-over-year to $44.5 million.

    • Pharmacy supply revenue in Q2 was softer than expected due to a stocking dynamic from pharmacy customers.

    • The full commercial launch timeline for the MINT patch pump was updated to the end of Q2 2027, subject to regulatory clearance.

    Guidance & targets

    5
    CategoryTargetConfidence
    Full-year 2026 Total Revenue
    $131 million to $136 million
    high materiality
    High
    Full-year 2026 New Patient Starts Reimbursed Through Pharmacy Channel
    37% to 39%
    medium materiality
    High
    Full-year 2026 Gross Margin
    58.5% to 59.5%
    high materiality
    High
    MINT Patch Pump Full Commercial Launch
    End of Q2 2027
    high materiality
    High
    Islet Indication Expansion to Type 2 Diabetes
    Mid-year 2027
    high materiality
    High

    Operational metrics

    10
    Net sales
    $32 million38% year over year
    Q2 FY26

    Driven predominantly by growth in new patient starts and growing installed base of users.

    New patient starts growth
    More than 10% but less than 20%compared to the prior quarter
    Q2 FY26

    Consistent with expectations.

    New patient starts from MDI users
    69%
    Q2 FY26

    Indicates expansion of the insulin pump market.

    New patient starts reimbursed via pharmacy channel
    High 30s percentagesimilar to the prior quarter
    Q2 FY26

    Consistent with expectations.

    Gross margin
    59.0%declining 45 basis points relative to the prior quarter and increasing 524 basis points relative to Q2 2025
    Q2 FY26

    Exceeded expectations, driven by high-margin recurring revenue from pharmacy install base and lower warranty rate. Viewed as a clean read on underlying gross margin profile.

    Total operating expenses
    $44.5 million37% year-over-year
    Q2 FY26

    Increase driven by expansion of field sales organization and increased marketing investments.

    Sales territories added
    At least 20
    H1 2026

    Achieved previously stated goal; new territories expected to contribute more meaningfully in H2 2026.

    Cash, cash equivalents, and investments
    $225 million
    As of June 30, 2026

    Company believes it is sufficiently capitalized to fund key initiatives.

    Type 2 new patient starts
    Greater than 30%
    Q2 FY26

    Of total new patient starts in Q2, indicating significant off-label use in this population.

    Warranty rate driver
    —lower
    Q2 FY26

    The screen upgrade to Gorilla Glass 3 resulted in less frequent screen breakage, favorably impacting gross margin and patient experience.

    Industry KPIs

    8
    MetricValueDetails
    New product launch ramp—
    Procedure volume growthMore than 10% but less than 20%%
    FCF conversion leverage guidance—
    Installed base system placements—
    Segment franchise organic growth38%%
    Consumables recurring revenue mix—
    Sales force commercial capacity buildAt least 20territories
    Indicated addressable patient populationGreater than 30%%

    Risks & headwinds

    3
    FDA warning letter remediation

    Not quantified

    Mitigation: Company has made considerable progress in remediating systems, particularly the complaints handling system and post-market surveillance systems, to meet agency expectations.

    Operating expenses increaseSecond half of 2026

    Modest increase expected

    Mitigation: Increase primarily driven by higher sales and R&D expenses, reflecting the full cost impact of sales territories added in H1 2026. No further sales force expansion expected in H2.

    Pharmacy supply revenue softnessQ2 FY26

    Impacted Q2 revenue

    Mitigation: Attributed to a stocking dynamic from pharmacy customers ending Q2 with less inventory. Patient demand and retention remain strong, suggesting a temporary impact rather than a fundamental issue.

    What to watch in Q3 FY26

    5

    MINT Launch Progress

    Next quarter
    CurrentFull commercial launch targeted end of Q2 2027, subject to FDA clearance.
    TargetFurther updates on FDA clearance and manufacturing scale-up.

    Why it matters

    MINT is a key pipeline product expected to redefine the patch pump category and drive future growth.

    We recently updated our expected timeline to achieve full commercial launch by the end of the second quarter of 2027, subject to regulatory clearance by the FDA.

    Q&A highlights

    7

    Competitors have criticized MINT's steel cannula. What percentage of durable pump patients use steel cannulas, and why is this not a problem for MINT?

    Sean Saint stated that for Beta Bionics, the mix is heavily skewed towards steel cannulas due to their durability and comfort. He emphasized that steel cannulas are smaller in diameter, comparable to an insulin pen needle, and suggested that the perceived discomfort of steel is often unfounded. He looks forward to head-to-head comparisons post-launch.

    “But what we look forward to is a day when somebody has tried the competition, tried us, and then we just ask them, which one did you prefer? And we know where the answer lies, because, you know, newsflash, we've used both.”

    asked by Felipe Lamar · answered by Sean Saint

    2 min read5 chapters

    Detailed Narrative

    01

    Real-World Data Transparency Initiative

    Beta Bionics has launched a new initiative to publish continuously refreshed, unfiltered real-world data for Islet users on its company website. This move aims to set a new standard for data transparency in the industry, providing healthcare providers, patients, payers, and investors with comprehensive outcomes data without selective populations or exclusion criteria. The company has received very positive feedback, indicating the positive experience Islet is delivering in the market.

    02

    Pharmacy Channel Strategy and Performance

    The pharmacy channel continues to be a critical component of Beta Bionics' commercial strategy, with a high 30s percentage of new patient starts in Q2 accessing Islet through this channel, consistent with expectations. The company maintains strong retention rates within its pharmacy install base. While Q2 pharmacy supply revenue was impacted by a stocking dynamic from customers, the underlying patient demand and retention remained strong, reinforcing the long-term viability of this reimbursement path.

    03

    MINT Patch Pump Development and Manufacturing Readiness

    Progress on the MINT patch pump is advancing, with the full commercial launch now targeted for the end of Q2 2027, pending FDA regulatory clearance. The company has achieved significant manufacturing milestones, including the retirement of manual production lines, establishment of a new cleanroom, and operation of semi-automated production lines. This readiness positions Beta Bionics to support anticipated demand at launch and as adoption grows, with confidence in its path to FDA clearance and scalable manufacturing.

    04

    Bi-Hormonal System and Islet Indication Expansion

    The bi-hormonal system is undergoing further iteration following a Phase IIa feasibility trial, with improvements focusing on glucagon excipient profile and dosing algorithms, expected to take less than one year before additional Phase IIa trials. Concurrently, Beta Bionics initiated enrollment in July for the pivotal PIPINAL trial to expand Islet's indication to adults with Type 2 diabetes, targeting mid-2027 FDA clearance. The company also plans to initiate a fully closed-loop pivotal trial for Type 1 and Type 2 diabetes in coming quarters.

    05

    Sales Force Expansion and Productivity

    Beta Bionics successfully expanded its field sales organization by at least 20 sales territories in the first half of 2026, achieving its previously stated goal. These new territories are expected to contribute more meaningfully to new patient starts in the second half of the year, as reps ramp up productivity. The company does not anticipate further sales force expansion in H2 2026, focusing instead on maximizing the effectiveness of its current commercial infrastructure.

    AI-generated summary of the company’s earnings call. Not investment advice.